Valuation dashboard for CRISPR Therapeutics AG (CRSP) with P/E N/A, P/B 2.93, EV/EBITDA -11.2 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code.
Analysis Summary
CRISPR Therapeutics AG reported revenue of $3.5M in the most recent fiscal year, growing at a 5-year CAGR of 37.3%.
Trailing-twelve-month margins: gross margin -5.6%, operating margin -21.0%, net margin -18.1%.
At $49.99 (closing price, November 2, 2026), CRSP has negative trailing earnings (P/E not meaningful) and an ROE of -25.59%. Market capitalisation stands at $4.8B.
Balance sheet quality for CRSP: debt-to-equity ratio of 0.47, current ratio of 16.12 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.93 |
| EV / EBITDA | -11.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $4.8B | 2.93 | -25.6% | |
| BEAM | Beam Therapeutics Inc. | $2.8B | 2.97 | -9.7% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.2B | 35.60 | 4.28 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $99.0B | 21.24 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $88.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $55.0B | 41.27 | 6.54 | 16.9% |
Price
| Price | $49.99 (closing price, November 2, 2026) |
| Market Cap | $4.8B |
| Exchange | NASDAQ |
| Country | CH |
Profitability
| Return on Equity | -25.59% |
| Return on Invested Capital | -21.88% |
| Return on Assets | -17.84% |
| Gross Margin | -558.91% |
| Operating Margin | -2,104.93% |
| Net Margin | -1,812.07% |
Related companies: BEAM · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of CRSP: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks